Nav: Home

New proposal published in RIO tackles problematic trial detection in

December 17, 2015

Clinical trials are crucial in determining the effectiveness of treatments and directly influence practical and policy decisions. However, their results could be even detrimental to real-life patients if data is fabricated or subject to errors. While it is about 2% of all researchers that admit to having manipulated their data, a new Dutch Fulbright project proposal, published via the innovative Research Ideas & Outcomes (RIO) Journal, suggests new methods to tackle these issues and to apply them to results reported in the database.

Decisions based on bad data, both clinical and policy ones made by medical doctors and governmental institutions, respectively, can pose direct risks on treated patients and the population in general. Such was the case of beta-blockers, for instance, used to be prescribed to cardiac patients in order to decrease perioperative mortality. However, a subsequent meta-analysis detected erroneous data in the related clinical trials. Moreover, it turned out that beta-blockers actually increase the risk of mortality.

The new Dutch Fulbright proposal led by Chris HJ Hartgerink, Tilburg University, Netherlands, and Dr. Stephen L George, Duke University, United States, proposes new additional statistical methods for erroneous data detection to provide an additional quality control filter for clinical trial results reported in the database.

Unfortunately, misleading data is not simply the product of bad practice, but could also result from human error or inadequate data handling. It is not even clear enough how often such mistakes or manipulations occur and have occurred in reality, let alone their prevalence in any science in particular. What is beyond doubt, however, is that additional methods and procedures of detecting bad data are needed in order to minimize the risk of bad decisions being taken when health and wellbeing are at stake.

"Detecting problematic data is a niche field with few experts around the world, despite its importance," further explains Chris HJ Hartgerink. "Systematic application remains absent and this project hopes to push this field into this area. New estimates of how prevalent problematic data are welcome, because we currently rely on self-report measures, which suffer from human bias."

Recently submitted to Fulbright, the 6-month project proposal has now been made open-access by the authors with RIO Journal, an innovative platform publishing all outputs of the research cycle, including: project proposals, data, methods, workflows, software, project reports and research articles.

"A grant proposal is a research output like any other but is only rewarded when it results in funding," says Chris HJ Hartgerink. "We know that many good proposals are rejected and consequently not rewarded. Publishing the grant proposal shows the output, makes it rewardable and can help improve it by post-publication peer review."
Original Source:

Hartgerink CHJ, George SL (2015) Problematic trial detection in Research Ideas and Outcomes 1: e7462. doi: 10.3897/rio.1.e7462

Additional Information:

The Research Ideas and Outcomes (RIO) Journal publishes all outputs of the research cycle, including: project proposals, data, methods, workflows, software, project reports and research articles together on a single collaborative platform offering one of the most transparent, open and public peer-review processes. Its scope encompasses all areas of academic research, including science, technology, the humanities and the social sciences.

Pensoft Publishers

Related Clinical Trials Articles:

Giving children a voice in clinical trials
Children as young as 8 years old with incurable cancer can reliably characterize the impact an experimental therapy has on their symptoms and quality of life -- even at the earliest stages of drug development -- making self-reported patient outcomes a potential new clinical trial endpoint.
Better health for women involved in clinical trials
Women who participate in obstetric and gynecology clinical trials experience improved health outcomes compared to those who are not involved in trials, according to research by Queen Mary University of London.
Final artificial pancreas clinical trials now open
Clinical trials are now enrolling to provide the final tests for a University of Virginia-developed artificial pancreas to automatically monitor and regulate blood-sugar levels in people with type 1 diabetes.
Why the bar needs to be raised for human clinical trials
Standards for authorizing first-time trials of drugs in humans are lax, and should be strengthened in several ways, McGill University researchers argue in a paper published today in Nature.
New drug formulary will help expedite use of agents in clinical trials
The National Cancer Institute (NCI) today launched a new drug formulary (the 'NCI Formulary') that will enable investigators at NCI-designated Cancer Centers to have quicker access to approved and investigational agents for use in preclinical studies and cancer clinical trials.
Review examines diversity in dermatology clinical trials
Racial and ethnic groups can be underrepresented in medical research.
Reshaping the future of global clinical trials practice
Researchers at the University of Liverpool have developed a new international guideline to help standardize how results from clinical trial studies are reported.
Fewer cardiovascular drugs being studied in clinical trials
The number of cardiovascular drugs in the research pipeline has declined across all phases of development in the last 20 years even as cardiovascular disease has become the No.
Sex hormones skew outcomes in clinical trials -- here's how
Clinical research often excludes females from their trials under the assumption that 'one size fits all,' that a painkiller or antidepressant will be equally effective in subjects of either sex, but a growing number of scientists are criticizing this approach.
Nearly half of pediatric clinical trials go unfinished or unpublished
Clinical trials in children commonly go either uncompleted or unpublished, finds a comprehensive study conducted by researchers at Boston Children's Hospital.

Related Clinical Trials Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#521 The Curious Life of Krill
Krill may be one of the most abundant forms of life on our planet... but it turns out we don't know that much about them. For a create that underpins a massive ocean ecosystem and lives in our oceans in massive numbers, they're surprisingly difficult to study. We sit down and shine some light on these underappreciated crustaceans with Stephen Nicol, Adjunct Professor at the University of Tasmania, Scientific Advisor to the Association of Responsible Krill Harvesting Companies, and author of the book "The Curious Life of Krill: A Conservation Story from the Bottom of the World".